P. Wiedeman

发表

DPPIV inhibition: promising therapy for the treatment of type 2 diabetes.

P. Wiedeman, 2007, Progress in medicinal chemistry.

Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome

P. Wiedeman, J. Trevillyan, 2005 .

Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.

L. Traphagen, U. Warrior, A. Molla, 2008, Bioorganic & medicinal chemistry letters.

Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds*

Julie A. Wilkins, U. Warrior, Yung-wu Chen, 2001, The Journal of Biological Chemistry.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

Inhibition of p56lckTyrosine Kinase by Isothiazolones

U. Warrior, Yung-wu Chen, P. Wiedeman, 1999 .

Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.

P. Wiedeman, J. Trevillyan, 2003, Current opinion in investigational drugs.

Practical Cu-catalyzed amination of functionalized heteroaryl halides

P. Wiedeman, V. Yeh, 2006 .

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

A relay approach to (+)-pleuromutilin. III. direct degradation of the natural product to the key diketone intermediate and its chemospecific functionalization

P. Wiedeman, L. Paquette, P. C. Bulman-Page, 1985 .

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

A relay to (+)-pleuromutilin. I. synthesis of a levorotatory tricyclic lactone subunit

P. Wiedeman, L. Paquette, 1985 .

Stereospecific syntheses of the four diastereomeric 2-amino-5-phenoxycyclopentanols

P. Wiedeman, J. Huffman, R. Barbuch, 1985 .

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Vincent S Stoll, K. Longenecker, V. Stoll, 2006, Biochemistry.

The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class.

R. Ulrich, P. Wiedeman, K. Marsh, 2002, Bioorganic & medicinal chemistry letters.

Synthesis of N-arylated oxazolidinones via a palladium catalyzed cross coupling reaction. Application to the synthesis of the antibacterial agent Dup-721

P. Wiedeman, S. Djurić, Marina A. Pliushchev, 2001 .

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

U. Warrior, P. Wiedeman, J. Trevillyan, 1999, Archives of biochemistry and biophysics.

(+)-Pleuromutilin synthetic studies. Examples of intramolecular hydrogen abstraction by the .beta.-carbon of a 2-cyclopentenone subunit with resultant .alpha.-coupling

J. Springer, P. Wiedeman, L. Paquette, 1988 .

Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.

H. Sham, Xiaofen Li, D. Beno, 2006, Journal of Medicinal Chemistry.

Rapamycin analogs with reduced systemic exposure.

P. Wiedeman, J. Trevillyan, G. Carter, 2005, Bioorganic & medicinal chemistry letters.